Sol Gel Technologies Ltd
SLGL41.580USD
-0.580-1.38%
Market hours （ET）Quotes delayed by 15 min
115.83MMarket Cap
LossP/E TTM
More Details of Sol Gel Technologies Ltd Company
Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
Sol Gel Technologies Ltd Info
Ticker SymbolSLGL
Company nameSol Gel Technologies Ltd
IPO dateFeb 01, 2018
CEO- -
Number of employees34
Security typeOrdinary Share
Fiscal year-endFeb 01
AddressGolda Meir 7
CityNESS-ZIONA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIsrael
Postal code- -
Phone97289313433
Websitehttp://www.sol-gel.com
Ticker SymbolSLGL
IPO dateFeb 01, 2018
CEO- -
Company Executives of Sol Gel Technologies Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Moshe (Mori) Arkin
Mr. Moshe (Mori) Arkin
Executive Chairman of the Board
Executive Chairman of the Board
143.26K
+275.67%
Dr. Karine Neimann, Ph.D.
Dr. Karine Neimann, Ph.D.
Vice President - Projects and Planning, Chief Chemist
Vice President - Projects and Planning, Chief Chemist
--
--
Ms. Yaffa Krindel
Ms. Yaffa Krindel
Independent Director
Independent Director
--
--
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Independent Director
Independent Director
--
--
Mr. Ran Gottfried
Mr. Ran Gottfried
Lead Independent Director
Lead Independent Director
--
--
Mr. Eyal Ben-Or
Mr. Eyal Ben-Or
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Hani Lerman
Ms. Hani Lerman
Director
Director
--
--
Dr. Ofra Levy-Hacham, Ph.D.
Dr. Ofra Levy-Hacham, Ph.D.
Vice President - Clinical and Regulatory Affairs
Vice President - Clinical and Regulatory Affairs
--
--
Dr. Ofer Toledano, Ph.D.
Dr. Ofer Toledano, Ph.D.
Vice President - Research and Development
Vice President - Research and Development
--
--
Mr. Nissim Bilman
Mr. Nissim Bilman
Vice President - Quality
Vice President - Quality
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Moshe (Mori) Arkin
Mr. Moshe (Mori) Arkin
Executive Chairman of the Board
Executive Chairman of the Board
143.26K
+275.67%
Dr. Karine Neimann, Ph.D.
Dr. Karine Neimann, Ph.D.
Vice President - Projects and Planning, Chief Chemist
Vice President - Projects and Planning, Chief Chemist
--
--
Ms. Yaffa Krindel
Ms. Yaffa Krindel
Independent Director
Independent Director
--
--
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Independent Director
Independent Director
--
--
Mr. Ran Gottfried
Mr. Ran Gottfried
Lead Independent Director
Lead Independent Director
--
--
Mr. Eyal Ben-Or
Mr. Eyal Ben-Or
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
M.Arkin Dermatology, Ltd.
64.86%
Opaleye Management Inc.
13.77%
Phoenix Investment and Finances Ltd
7.83%
Arkin (Moshe)
5.14%
Migdal Insurance and Financial Holdings Ltd
4.41%
Other
3.99%
Shareholders
Shareholders
Proportion
M.Arkin Dermatology, Ltd.
64.86%
Opaleye Management Inc.
13.77%
Phoenix Investment and Finances Ltd
7.83%
Arkin (Moshe)
5.14%
Migdal Insurance and Financial Holdings Ltd
4.41%
Other
3.99%
Shareholder Types
Shareholders
Proportion
Corporation
64.86%
Hedge Fund
13.77%
Investment Advisor
7.86%
Individual Investor
5.14%
Insurance Company
4.68%
Research Firm
0.16%
Other
3.53%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
35
286.02K
10.27%
-480.14K
2025Q2
36
2.50M
89.88%
-104.83K
2025Q1
37
2.45M
84.60%
+78.00K
2024Q4
35
23.50M
84.37%
-314.30K
2024Q3
34
23.55M
84.52%
-115.49K
2024Q2
31
25.52M
91.61%
+1.51M
2024Q1
30
23.87M
85.67%
+1.61M
2023Q4
31
22.12M
83.66%
-222.95K
2023Q3
30
22.20M
83.99%
-4.35K
2023Q2
29
22.04M
83.43%
-335.52K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
M.Arkin Dermatology, Ltd.
1.81M
64.86%
--
--
Jun 11, 2025
Opaleye Management Inc.
139.39K
5%
+139.39K
--
Aug 22, 2025
Phoenix Investment and Finances Ltd
247.02K
8.87%
+1.00
+0.00%
Jun 30, 2025
Arkin (Moshe)
143.26K
5.14%
+105.12K
+275.67%
Jun 11, 2025
Migdal Insurance and Financial Holdings Ltd
122.75K
4.41%
--
--
Jun 30, 2025
Morgan Stanley & Co. LLC
5.33K
0.19%
-3.90K
-42.24%
Jun 30, 2025
Steward Partners Investment Advisory, LLC
316.00
0.01%
-200.00
-38.76%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
308.00
0.01%
-1.00
-0.32%
Jun 30, 2025
SBI Securities Co., Ltd.
100.00
0%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
Invesco Raymond James SB-1 Equity ETF
0%
Invesco Raymond James SB-1 Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
May 01, 2025
Merger
10→1
Date
Type
Ratio
May 01, 2025
Merger
10→1
FAQs
Who are the top five shareholders of Sol Gel Technologies Ltd?
The top five shareholders of Sol Gel Technologies Ltd are:
M.Arkin Dermatology, Ltd. holds 1.81M shares, accounting for 64.86% of the total shares.
Opaleye Management Inc. holds 139.39K shares, accounting for 5.00% of the total shares.
Phoenix Investment and Finances Ltd holds 247.02K shares, accounting for 8.87% of the total shares.
Arkin (Moshe) holds 143.26K shares, accounting for 5.14% of the total shares.
Migdal Insurance and Financial Holdings Ltd holds 122.75K shares, accounting for 4.41% of the total shares.
M.Arkin Dermatology, Ltd. holds 1.81M shares, accounting for 64.86% of the total shares.
Opaleye Management Inc. holds 139.39K shares, accounting for 5.00% of the total shares.
Phoenix Investment and Finances Ltd holds 247.02K shares, accounting for 8.87% of the total shares.
Arkin (Moshe) holds 143.26K shares, accounting for 5.14% of the total shares.
Migdal Insurance and Financial Holdings Ltd holds 122.75K shares, accounting for 4.41% of the total shares.
What are the top three shareholder types of Sol Gel Technologies Ltd?
The top three shareholder types of Sol Gel Technologies Ltd are:
M.Arkin Dermatology, Ltd.
Opaleye Management Inc.
Phoenix Investment and Finances Ltd
M.Arkin Dermatology, Ltd.
Opaleye Management Inc.
Phoenix Investment and Finances Ltd
How many institutions hold shares of Sol Gel Technologies Ltd (SLGL)?
As of 2025Q3, 35 institutions hold shares of Sol Gel Technologies Ltd, with a combined market value of approximately 286.02K, accounting for 10.27% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -79.61%.
What is the biggest source of revenue for Sol Gel Technologies Ltd?
In --, the -- business generated the highest revenue for Sol Gel Technologies Ltd, amounting to -- and accounting for --% of total revenue.
